SIMILAR PATTERN OF AMINO ACIDS MAPPED TO 'SM5'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1GTI_D_CCSD47_0 (GLUTATHIONE S-TRANSFERASE)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	4 / 7	TRP A 423 THR A 353 LEU A 351 GLY A 366	SM5 A 1 (-4.3A) None None None	0.99A	1gtiD-3omvA: undetectable	1gtiD-3omvA: 20.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1GTI_E_CCSE47_0 (GLUTATHIONE S-TRANSFERASE)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	4 / 7	TRP A 423 THR A 353 LEU A 351 GLY A 366	SM5 A 1 (-4.3A) None None None	0.88A	1gtiE-3omvA: undetectable	1gtiE-3omvA: 20.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1MXG_A_ACRA443_1 (ALPHA AMYLASE)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	4 / 8	SER A 471 ASN A 473 ASP A 468 GLU A 393	None None None SM5 A 1 (-4.3A)	1.09A	1mxgA-3omvA: undetectable	1mxgA-3omvA: 17.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UWH_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	10 / 12	ALA A 373 GLU A 393 LEU A 397 LEU A 406 THR A 421 TRP A 423 CYH A 424 LEU A 459 HIS A 466 GLY A 485	SM5 A 1 (-3.6A) SM5 A 1 (-4.3A) None None SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 ( 4.4A) None None None	0.94A	1uwhA-3omvA: 36.3	1uwhA-3omvA: 72.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UWH_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	9 / 12	ALA A 373 LEU A 397 LEU A 406 THR A 421 TRP A 423 LEU A 459 HIS A 466 GLY A 485 PHE A 475	SM5 A 1 (-3.6A) None None SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) None None None SM5 A 1 (-3.0A)	1.21A	1uwhA-3omvA: 36.3	1uwhA-3omvA: 72.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UWH_A_BAXA1723_2 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	5 / 6	ILE A 355 VAL A 363 VAL A 396 ILE A 405 ILE A 464	SM5 A 1 (-4.3A) SM5 A 1 (-4.0A) None None None	0.53A	1uwhA-3omvA: 36.4	1uwhA-3omvA: 72.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UWH_B_BAXB1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	10 / 12	ALA A 373 LYS A 375 GLU A 393 LEU A 397 LEU A 406 THR A 421 TRP A 423 CYH A 424 LEU A 459 GLY A 485	SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) SM5 A 1 (-4.3A) None None SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 ( 4.4A) None None	0.95A	1uwhB-3omvA: 36.3	1uwhB-3omvA: 72.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UWH_B_BAXB1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	10 / 12	ALA A 373 LYS A 375 LEU A 397 LEU A 406 THR A 421 TRP A 423 CYH A 424 LEU A 459 HIS A 466 GLY A 485	SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) None None SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 ( 4.4A) None None None	0.81A	1uwhB-3omvA: 36.3	1uwhB-3omvA: 72.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UWJ_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	9 / 12	VAL A 363 ALA A 373 GLU A 393 LEU A 406 THR A 421 TRP A 423 CYH A 424 LEU A 459 GLY A 485	SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) SM5 A 1 (-4.3A) None SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 ( 4.4A) None None	0.96A	1uwjA-3omvA: 13.2	1uwjA-3omvA: 72.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UWJ_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	10 / 12	VAL A 363 ALA A 373 THR A 400 LEU A 406 THR A 421 TRP A 423 CYH A 424 LEU A 459 HIS A 466 GLY A 485	SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) None None SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 ( 4.4A) None None None	0.71A	1uwjA-3omvA: 13.2	1uwjA-3omvA: 72.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UWJ_A_BAXA1723_2 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	5 / 7	ILE A 355 LYS A 375 LEU A 397 ILE A 405 ILE A 464	SM5 A 1 (-4.3A) SM5 A 1 (-3.5A) None None None	0.71A	1uwjA-3omvA: 13.2	1uwjA-3omvA: 72.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UWJ_B_BAXB1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	10 / 12	ILE A 355 VAL A 363 ALA A 373 GLU A 393 LEU A 406 THR A 421 TRP A 423 CYH A 424 LEU A 459 GLY A 485	SM5 A 1 (-4.3A) SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) SM5 A 1 (-4.3A) None SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 ( 4.4A) None None	0.93A	1uwjB-3omvA: 13.4	1uwjB-3omvA: 72.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UWJ_B_BAXB1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	10 / 12	ILE A 355 VAL A 363 ALA A 373 LEU A 406 THR A 421 TRP A 423 CYH A 424 LEU A 459 HIS A 466 GLY A 485	SM5 A 1 (-4.3A) SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) None SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 ( 4.4A) None None None	0.72A	1uwjB-3omvA: 13.4	1uwjB-3omvA: 72.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1VPT_A_SAMA400_0 (VP39)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	5 / 12	LEU A 397 GLY A 488 VAL A 374 ALA A 373 LEU A 351	None None None SM5 A 1 (-3.6A) None	0.93A	1vptA-3omvA: undetectable	1vptA-3omvA: 22.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3GCS_A_BAXA401_1 (MITOGEN-ACTIVATED PROTEIN KINASE 14)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	5 / 12	ALA A 373 GLU A 393 LEU A 397 THR A 421 HIS A 466	SM5 A 1 (-3.6A) SM5 A 1 (-4.3A) None SM5 A 1 (-4.4A) None	0.89A	3gcsA-3omvA: 19.9	3gcsA-3omvA: 27.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3GCS_A_BAXA401_1 (MITOGEN-ACTIVATED PROTEIN KINASE 14)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	5 / 12	VAL A 363 ALA A 373 GLU A 393 LEU A 397 THR A 421	SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) SM5 A 1 (-4.3A) None SM5 A 1 (-4.4A)	0.59A	3gcsA-3omvA: 19.9	3gcsA-3omvA: 27.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3HEC_A_STIA1_1 (MITOGEN-ACTIVATED PROTEIN KINASE 14)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	5 / 12	ALA A 373 LYS A 375 GLU A 393 LEU A 397 THR A 421	SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) SM5 A 1 (-4.3A) None SM5 A 1 (-4.4A)	0.65A	3hecA-3omvA: 20.6	3hecA-3omvA: 27.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3HEG_A_BAXA1_1 (MITOGEN-ACTIVATED PROTEIN KINASE 14)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	VAL A 363 ALA A 373 LYS A 375 GLU A 393 LEU A 397 THR A 421	SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) SM5 A 1 (-4.3A) None SM5 A 1 (-4.4A)	0.59A	3hegA-3omvA: 20.2	3hegA-3omvA: 27.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MSS_D_STID1_2 (TYROSINE-PROTEIN KINASE ABL1)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	4 / 6	VAL A 363 LYS A 375 VAL A 396 ILE A 419	SM5 A 1 (-4.0A) SM5 A 1 (-3.5A) None SM5 A 1 ( 4.3A)	0.73A	3mssD-3omvA: 26.6	3mssD-3omvA: 29.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OG7_A_032A1_1 (AKAP9-BRAF FUSION PROTEIN)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	10 / 12	ILE A 355 VAL A 363 ALA A 373 LEU A 397 LEU A 406 THR A 421 TRP A 423 CYH A 424 PHE A 475 PHE A 487	SM5 A 1 (-4.3A) SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) None None SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 ( 4.4A) SM5 A 1 (-3.0A) None	0.79A	3og7A-3omvA: 34.5	3og7A-3omvA: 72.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OG7_A_032A1_1 (AKAP9-BRAF FUSION PROTEIN)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	10 / 12	ILE A 355 VAL A 363 ALA A 373 LYS A 375 LEU A 397 LEU A 406 THR A 421 TRP A 423 PHE A 475 PHE A 487	SM5 A 1 (-4.3A) SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) None None SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 (-3.0A) None	0.81A	3og7A-3omvA: 34.5	3og7A-3omvA: 72.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OG7_A_032A1_1 (AKAP9-BRAF FUSION PROTEIN)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	ILE A 355 VAL A 363 ALA A 373 LYS A 375 TRP A 423 PHE A 475 GLY A 488	SM5 A 1 (-4.3A) SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) SM5 A 1 (-4.3A) SM5 A 1 (-3.0A) None	1.05A	3og7A-3omvA: 34.5	3og7A-3omvA: 72.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OG7_A_032A1_1 (AKAP9-BRAF FUSION PROTEIN)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	ILE A 355 VAL A 363 ALA A 373 TRP A 423 CYH A 424 PHE A 475 GLY A 488	SM5 A 1 (-4.3A) SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) SM5 A 1 (-4.3A) SM5 A 1 ( 4.4A) SM5 A 1 (-3.0A) None	0.97A	3og7A-3omvA: 34.5	3og7A-3omvA: 72.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OHT_A_1N1A1000_1 (P38A)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	GLY A 356 VAL A 363 ALA A 373 LYS A 375 LEU A 397 THR A 421	SM5 A 1 ( 4.9A) SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) None SM5 A 1 (-4.4A)	0.72A	3ohtA-3omvA: 16.9	3ohtA-3omvA: 29.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RZV_A_032A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	ALA A 373 LEU A 406 ILE A 419 THR A 421 SER A 427 SER A 428 PHE A 475	SM5 A 1 (-3.6A) None SM5 A 1 ( 4.3A) SM5 A 1 (-4.4A) None None SM5 A 1 (-3.0A)	0.77A	4rzvA-3omvA: 12.9	4rzvA-3omvA: 70.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RZV_A_032A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	9 / 12	ALA A 373 LEU A 406 ILE A 419 THR A 421 TRP A 423 SER A 427 PHE A 475 GLY A 485 PHE A 487	SM5 A 1 (-3.6A) None SM5 A 1 ( 4.3A) SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) None SM5 A 1 (-3.0A) None None	0.85A	4rzvA-3omvA: 12.9	4rzvA-3omvA: 70.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RZV_A_032A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	5 / 12	ALA A 373 LEU A 406 THR A 421 TRP A 423 SER A 427	SM5 A 1 (-3.6A) None SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) None	0.98A	4rzvA-3omvA: 12.9	4rzvA-3omvA: 70.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RZV_A_032A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	ALA A 373 LYS A 375 ILE A 419 THR A 421 SER A 427 SER A 428 PHE A 475	SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) SM5 A 1 ( 4.3A) SM5 A 1 (-4.4A) None None SM5 A 1 (-3.0A)	0.80A	4rzvA-3omvA: 12.9	4rzvA-3omvA: 70.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RZV_A_032A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	9 / 12	ALA A 373 LYS A 375 ILE A 419 THR A 421 TRP A 423 SER A 427 PHE A 475 GLY A 485 PHE A 487	SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) SM5 A 1 ( 4.3A) SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) None SM5 A 1 (-3.0A) None None	0.87A	4rzvA-3omvA: 12.9	4rzvA-3omvA: 70.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RZV_A_032A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	8 / 12	ALA A 373 LYS A 375 ILE A 419 TRP A 423 SER A 427 PHE A 475 GLY A 485 GLY A 488	SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) SM5 A 1 ( 4.3A) SM5 A 1 (-4.3A) None SM5 A 1 (-3.0A) None None	1.21A	4rzvA-3omvA: 12.9	4rzvA-3omvA: 70.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RZV_A_032A801_2 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	4 / 5	ILE A 355 VAL A 363 PHE A 408 CYH A 424	SM5 A 1 (-4.3A) SM5 A 1 (-4.0A) None SM5 A 1 ( 4.4A)	0.46A	4rzvA-3omvA: 12.9	4rzvA-3omvA: 70.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RZV_B_032B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	VAL A 363 ALA A 373 LEU A 406 THR A 421 TRP A 423 CYH A 424 SER A 427	SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) None SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 ( 4.4A) None	1.05A	4rzvB-3omvA: 33.1	4rzvB-3omvA: 70.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RZV_B_032B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	10 / 12	VAL A 363 ALA A 373 LYS A 375 LEU A 406 THR A 421 TRP A 423 CYH A 424 PHE A 475 GLY A 485 PHE A 487	SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) None SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 ( 4.4A) SM5 A 1 (-3.0A) None None	0.95A	4rzvB-3omvA: 33.1	4rzvB-3omvA: 70.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RZV_B_032B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	9 / 12	VAL A 363 ALA A 373 LYS A 375 LEU A 406 THR A 421 TRP A 423 CYH A 424 SER A 428 PHE A 475	SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) None SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 ( 4.4A) None SM5 A 1 (-3.0A)	1.00A	4rzvB-3omvA: 33.1	4rzvB-3omvA: 70.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RZV_B_032B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	8 / 12	VAL A 363 ALA A 373 LYS A 375 TRP A 423 CYH A 424 PHE A 475 GLY A 485 GLY A 488	SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) SM5 A 1 (-4.3A) SM5 A 1 ( 4.4A) SM5 A 1 (-3.0A) None None	1.30A	4rzvB-3omvA: 33.1	4rzvB-3omvA: 70.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XV2_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	ALA A 373 LYS A 375 THR A 421 PHE A 475 GLY A 485 PHE A 487	SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) SM5 A 1 (-4.4A) SM5 A 1 (-3.0A) None None	0.83A	4xv2A-3omvA: 35.1	4xv2A-3omvA: 72.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XV2_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	9 / 12	VAL A 363 ALA A 373 LEU A 406 THR A 421 TRP A 423 CYH A 424 PHE A 475 GLY A 485 PHE A 487	SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) None SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 ( 4.4A) SM5 A 1 (-3.0A) None None	0.78A	4xv2A-3omvA: 35.1	4xv2A-3omvA: 72.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XV2_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	9 / 12	VAL A 363 ALA A 373 LEU A 406 TRP A 423 CYH A 424 PHE A 475 GLY A 485 ASP A 486 PHE A 487	SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) None SM5 A 1 (-4.3A) SM5 A 1 ( 4.4A) SM5 A 1 (-3.0A) None SM5 A 1 (-3.5A) None	1.09A	4xv2A-3omvA: 35.1	4xv2A-3omvA: 72.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XV2_A_P06A801_2 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	4 / 4	GLY A 358 LEU A 397 PHE A 408 ILE A 419	None None None SM5 A 1 ( 4.3A)	0.71A	4xv2A-3omvA: 35.1	4xv2A-3omvA: 72.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XV2_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	9 / 12	ALA A 373 LEU A 397 LEU A 406 THR A 421 TRP A 423 CYH A 424 PHE A 475 GLY A 485 PHE A 487	SM5 A 1 (-3.6A) None None SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 ( 4.4A) SM5 A 1 (-3.0A) None None	0.77A	4xv2B-3omvA: 35.4	4xv2B-3omvA: 72.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XV2_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	8 / 12	ALA A 373 LEU A 406 TRP A 423 CYH A 424 PHE A 475 GLY A 485 ASP A 486 PHE A 487	SM5 A 1 (-3.6A) None SM5 A 1 (-4.3A) SM5 A 1 ( 4.4A) SM5 A 1 (-3.0A) None SM5 A 1 (-3.5A) None	0.99A	4xv2B-3omvA: 35.4	4xv2B-3omvA: 72.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XV2_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	ALA A 373 LYS A 375 LEU A 397 THR A 421 PHE A 475 GLY A 485 PHE A 487	SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) None SM5 A 1 (-4.4A) SM5 A 1 (-3.0A) None None	0.89A	4xv2B-3omvA: 35.4	4xv2B-3omvA: 72.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XV2_B_P06B801_2 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	4 / 4	GLY A 358 VAL A 363 PHE A 408 ILE A 419	None SM5 A 1 (-4.0A) None SM5 A 1 ( 4.3A)	0.44A	4xv2B-3omvA: 35.4	4xv2B-3omvA: 72.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5CSW_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	10 / 12	VAL A 363 ALA A 373 LEU A 397 LEU A 406 THR A 421 TRP A 423 CYH A 424 PHE A 475 GLY A 485 PHE A 487	SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) None None SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 ( 4.4A) SM5 A 1 (-3.0A) None None	0.84A	5cswA-3omvA: 35.4	5cswA-3omvA: 75.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5CSW_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	9 / 12	VAL A 363 ALA A 373 LYS A 375 LEU A 397 THR A 421 TRP A 423 PHE A 475 GLY A 485 PHE A 487	SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) None SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 (-3.0A) None None	0.95A	5cswA-3omvA: 35.4	5cswA-3omvA: 75.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5CSW_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	8 / 12	ALA A 373 LYS A 375 LEU A 397 THR A 421 TRP A 423 PHE A 475 GLY A 485 PHE A 487	SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) None SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 (-3.0A) None None	0.95A	5cswB-3omvA: 34.5	5cswB-3omvA: 75.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5CSW_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	10 / 12	VAL A 363 ALA A 373 LEU A 397 LEU A 406 THR A 421 TRP A 423 CYH A 424 PHE A 475 GLY A 485 PHE A 487	SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) None None SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 ( 4.4A) SM5 A 1 (-3.0A) None None	0.85A	5cswB-3omvA: 34.5	5cswB-3omvA: 75.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5H2U_B_1N1B501_1 (PROTEIN-TYROSINE KINASE 6)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	VAL A 363 ALA A 373 LEU A 406 ILE A 419 THR A 421 GLY A 485 ASP A 486	SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) None SM5 A 1 ( 4.3A) SM5 A 1 (-4.4A) None SM5 A 1 (-3.5A)	0.80A	5h2uB-3omvA: 19.6	5h2uB-3omvA: 32.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5H2U_C_1N1C501_1 (PROTEIN-TYROSINE KINASE 6)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	5 / 12	ALA A 373 LEU A 406 ILE A 419 THR A 421 GLY A 485	SM5 A 1 (-3.6A) None SM5 A 1 ( 4.3A) SM5 A 1 (-4.4A) None	0.64A	5h2uC-3omvA: 27.1	5h2uC-3omvA: 32.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5H2U_D_1N1D504_1 (PROTEIN-TYROSINE KINASE 6)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	VAL A 363 ALA A 373 LEU A 406 ILE A 419 THR A 421 GLY A 485	SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) None SM5 A 1 ( 4.3A) SM5 A 1 (-4.4A) None	0.66A	5h2uD-3omvA: 27.2	5h2uD-3omvA: 32.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HES_B_032B401_1 (MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	VAL A 363 ALA A 373 LYS A 375 ILE A 419 THR A 421 PHE A 487	SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) SM5 A 1 ( 4.3A) SM5 A 1 (-4.4A) None	0.78A	5hesB-3omvA: 26.1	5hesB-3omvA: 30.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HI2_A_BAXA801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	10 / 12	ALA A 373 LYS A 375 GLU A 393 LEU A 397 LEU A 406 THR A 421 TRP A 423 CYH A 424 LEU A 459 GLY A 485	SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) SM5 A 1 (-4.3A) None None SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 ( 4.4A) None None	0.95A	5hi2A-3omvA: 33.4	5hi2A-3omvA: 71.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HI2_A_BAXA801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	10 / 12	ALA A 373 LYS A 375 LEU A 397 LEU A 406 THR A 421 TRP A 423 CYH A 424 LEU A 459 HIS A 466 GLY A 485	SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) None None SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 ( 4.4A) None None None	0.82A	5hi2A-3omvA: 33.4	5hi2A-3omvA: 71.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	8 / 12	GLY A 358 ALA A 373 LYS A 375 LEU A 406 ILE A 419 THR A 421 PHE A 475 GLY A 485	None SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) None SM5 A 1 ( 4.3A) SM5 A 1 (-4.4A) SM5 A 1 (-3.0A) None	0.92A	5hieA-3omvA: 34.7	5hieA-3omvA: 77.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	GLY A 358 VAL A 363 ALA A 373 LEU A 397 ILE A 419 THR A 421 TRP A 423	None SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) None SM5 A 1 ( 4.3A) SM5 A 1 (-4.4A) SM5 A 1 (-4.3A)	1.02A	5hieA-3omvA: 34.7	5hieA-3omvA: 77.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	9 / 12	GLY A 358 VAL A 363 ALA A 373 LEU A 406 ILE A 419 THR A 421 TRP A 423 PHE A 475 GLY A 485	None SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) None SM5 A 1 ( 4.3A) SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 (-3.0A) None	0.79A	5hieA-3omvA: 34.7	5hieA-3omvA: 77.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_A_P06A801_2 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	4 / 7	ILE A 355 CYH A 424 ASP A 486 PHE A 487	SM5 A 1 (-4.3A) SM5 A 1 ( 4.4A) SM5 A 1 (-3.5A) None	0.91A	5hieA-3omvA: 34.7	5hieA-3omvA: 77.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_A_P06A801_2 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	4 / 7	ILE A 355 GLY A 356 PHE A 408 CYH A 424	SM5 A 1 (-4.3A) SM5 A 1 ( 4.9A) None SM5 A 1 ( 4.4A)	0.51A	5hieA-3omvA: 34.7	5hieA-3omvA: 77.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	GLY A 358 ALA A 373 LYS A 375 LEU A 406 THR A 421 PHE A 475 GLY A 485	None SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) None SM5 A 1 (-4.4A) SM5 A 1 (-3.0A) None	0.91A	5hieB-3omvA: 34.8	5hieB-3omvA: 77.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	9 / 12	GLY A 358 VAL A 363 ALA A 373 LEU A 406 ILE A 419 THR A 421 TRP A 423 PHE A 475 GLY A 485	None SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) None SM5 A 1 ( 4.3A) SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 (-3.0A) None	0.81A	5hieB-3omvA: 34.8	5hieB-3omvA: 77.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_B_P06B801_2 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	5 / 7	ILE A 355 GLY A 356 CYH A 424 ASP A 486 PHE A 487	SM5 A 1 (-4.3A) SM5 A 1 ( 4.9A) SM5 A 1 ( 4.4A) SM5 A 1 (-3.5A) None	1.10A	5hieB-3omvA: 34.8	5hieB-3omvA: 77.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_B_P06B801_2 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	4 / 7	ILE A 355 GLY A 356 LEU A 397 PHE A 408	SM5 A 1 (-4.3A) SM5 A 1 ( 4.9A) None None	0.87A	5hieB-3omvA: 34.8	5hieB-3omvA: 77.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_B_P06B801_2 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	4 / 7	ILE A 355 GLY A 356 PHE A 408 CYH A 424	SM5 A 1 (-4.3A) SM5 A 1 ( 4.9A) None SM5 A 1 ( 4.4A)	0.50A	5hieB-3omvA: 34.8	5hieB-3omvA: 77.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_C_P06C801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	9 / 12	GLY A 356 GLY A 358 VAL A 363 ALA A 373 LEU A 406 THR A 421 TRP A 423 PHE A 475 GLY A 485	SM5 A 1 ( 4.9A) None SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) None SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 (-3.0A) None	0.78A	5hieC-3omvA: 34.8	5hieC-3omvA: 77.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_C_P06C801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	GLY A 358 ALA A 373 LYS A 375 LEU A 406 THR A 421 PHE A 475 GLY A 485	None SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) None SM5 A 1 (-4.4A) SM5 A 1 (-3.0A) None	0.89A	5hieC-3omvA: 34.8	5hieC-3omvA: 77.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_C_P06C801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	VAL A 363 ALA A 373 LEU A 406 TRP A 423 PHE A 475 GLY A 485 ASP A 486	SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) None SM5 A 1 (-4.3A) SM5 A 1 (-3.0A) None SM5 A 1 (-3.5A)	1.17A	5hieC-3omvA: 34.8	5hieC-3omvA: 77.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_C_P06C801_2 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	4 / 7	ILE A 355 ILE A 419 CYH A 424 PHE A 487	SM5 A 1 (-4.3A) SM5 A 1 ( 4.3A) SM5 A 1 ( 4.4A) None	0.69A	5hieC-3omvA: 34.8	5hieC-3omvA: 77.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_C_P06C801_2 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	4 / 7	ILE A 355 PHE A 408 ILE A 419 ASN A 472	SM5 A 1 (-4.3A) None SM5 A 1 ( 4.3A) SM5 A 1 (-3.9A)	0.70A	5hieC-3omvA: 34.8	5hieC-3omvA: 77.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_C_P06C801_2 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	4 / 7	ILE A 355 PHE A 408 ILE A 419 CYH A 424	SM5 A 1 (-4.3A) None SM5 A 1 ( 4.3A) SM5 A 1 ( 4.4A)	0.46A	5hieC-3omvA: 34.8	5hieC-3omvA: 77.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_C_P06C801_2 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	4 / 7	VAL A 396 PHE A 408 ILE A 419 ASN A 472	None None SM5 A 1 ( 4.3A) SM5 A 1 (-3.9A)	0.98A	5hieC-3omvA: 34.8	5hieC-3omvA: 77.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_D_P06D801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	8 / 12	GLY A 358 ALA A 373 LYS A 375 LEU A 406 ILE A 419 THR A 421 PHE A 475 GLY A 485	None SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) None SM5 A 1 ( 4.3A) SM5 A 1 (-4.4A) SM5 A 1 (-3.0A) None	0.93A	5hieD-3omvA: 34.6	5hieD-3omvA: 77.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_D_P06D801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	9 / 12	GLY A 358 VAL A 363 ALA A 373 LEU A 406 ILE A 419 THR A 421 TRP A 423 PHE A 475 GLY A 485	None SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) None SM5 A 1 ( 4.3A) SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 (-3.0A) None	0.79A	5hieD-3omvA: 34.6	5hieD-3omvA: 77.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_D_P06D801_2 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	5 / 8	ILE A 355 GLY A 356 CYH A 424 ASP A 486 PHE A 487	SM5 A 1 (-4.3A) SM5 A 1 ( 4.9A) SM5 A 1 ( 4.4A) SM5 A 1 (-3.5A) None	1.08A	5hieD-3omvA: 34.6	5hieD-3omvA: 77.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_D_P06D801_2 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	4 / 8	ILE A 355 GLY A 356 PHE A 408 ASN A 472	SM5 A 1 (-4.3A) SM5 A 1 ( 4.9A) None SM5 A 1 (-3.9A)	0.88A	5hieD-3omvA: 34.6	5hieD-3omvA: 77.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_D_P06D801_2 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	4 / 8	ILE A 355 GLY A 356 PHE A 408 CYH A 424	SM5 A 1 (-4.3A) SM5 A 1 ( 4.9A) None SM5 A 1 ( 4.4A)	0.50A	5hieD-3omvA: 34.6	5hieD-3omvA: 77.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VCV_A_1N1A404_1 (MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	ALA A 373 LYS A 375 GLU A 393 THR A 421 PHE A 475 GLY A 485	SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) SM5 A 1 (-4.3A) SM5 A 1 (-4.4A) SM5 A 1 (-3.0A) None	0.83A	5vcvA-3omvA: 23.1	5vcvA-3omvA: 27.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VCY_A_DB8A401_1 (MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE)	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	VAL A 363 ALA A 373 LYS A 375 GLU A 393 THR A 421 CYH A 424 PHE A 475	SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) SM5 A 1 (-4.3A) SM5 A 1 (-4.4A) SM5 A 1 ( 4.4A) SM5 A 1 (-3.0A)	0.98A	5vcyA-3omvA: 23.1	5vcyA-3omvA: 27.99

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1GTI_D_CCSD47_0","GLUTATHIONE S-TRANSFERASE","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",4,"TRP A 423;THR A 353;LEU A 351;GLY A 366","SM5 A   1 (-4.3A);None;None;None","0.99A","1gtiD-3omvA:undetectable",null],["1GTI_E_CCSE47_0","GLUTATHIONE S-TRANSFERASE","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",4,"TRP A 423;THR A 353;LEU A 351;GLY A 366","SM5 A   1 (-4.3A);None;None;None","0.88A","1gtiE-3omvA:undetectable","1gtiD-3omvA:20.52"],["1MXG_A_ACRA443_1","ALPHA AMYLASE","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",4,"SER A 471;ASN A 473;ASP A 468;GLU A 393","None;None;None;SM5 A   1 (-4.3A)","1.09A","1mxgA-3omvA:undetectable","1gtiE-3omvA:20.52"],["1UWH_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",10,"ALA A 373;GLU A 393;LEU A 397;LEU A 406;THR A 421;TRP A 423;CYH A 424;LEU A 459;HIS A 466;GLY A 485","SM5 A   1 (-3.6A);SM5 A   1 (-4.3A);None;None;SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 ( 4.4A);None;None;None","0.94A","1uwhA-3omvA:36.3","1mxgA-3omvA:17.35"],["1UWH_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",9,"ALA A 373;LEU A 397;LEU A 406;THR A 421;TRP A 423;LEU A 459;HIS A 466;GLY A 485;PHE A 475","SM5 A   1 (-3.6A);None;None;SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);None;None;None;SM5 A   1 (-3.0A)","1.21A","1uwhA-3omvA:36.3","1uwhA-3omvA:72.70"],["1UWH_A_BAXA1723_2","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",5,"ILE A 355;VAL A 363;VAL A 396;ILE A 405;ILE A 464","SM5 A   1 (-4.3A);SM5 A   1 (-4.0A);None;None;None","0.53A","1uwhA-3omvA:36.4","1uwhA-3omvA:72.70"],["1UWH_B_BAXB1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",10,"ALA A 373;LYS A 375;GLU A 393;LEU A 397;LEU A 406;THR A 421;TRP A 423;CYH A 424;LEU A 459;GLY A 485","SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);SM5 A   1 (-4.3A);None;None;SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 ( 4.4A);None;None","0.95A","1uwhB-3omvA:36.3","1uwhA-3omvA:72.70"],["1UWH_B_BAXB1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",10,"ALA A 373;LYS A 375;LEU A 397;LEU A 406;THR A 421;TRP A 423;CYH A 424;LEU A 459;HIS A 466;GLY A 485","SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);None;None;SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 ( 4.4A);None;None;None","0.81A","1uwhB-3omvA:36.3","1uwhB-3omvA:72.70"],["1UWJ_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",9,"VAL A 363;ALA A 373;GLU A 393;LEU A 406;THR A 421;TRP A 423;CYH A 424;LEU A 459;GLY A 485","SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);SM5 A   1 (-4.3A);None;SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 ( 4.4A);None;None","0.96A","1uwjA-3omvA:13.2","1uwhB-3omvA:72.70"],["1UWJ_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",10,"VAL A 363;ALA A 373;THR A 400;LEU A 406;THR A 421;TRP A 423;CYH A 424;LEU A 459;HIS A 466;GLY A 485","SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);None;None;SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 ( 4.4A);None;None;None","0.71A","1uwjA-3omvA:13.2","1uwjA-3omvA:72.70"],["1UWJ_A_BAXA1723_2","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",5,"ILE A 355;LYS A 375;LEU A 397;ILE A 405;ILE A 464","SM5 A   1 (-4.3A);SM5 A   1 (-3.5A);None;None;None","0.71A","1uwjA-3omvA:13.2","1uwjA-3omvA:72.70"],["1UWJ_B_BAXB1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",10,"ILE A 355;VAL A 363;ALA A 373;GLU A 393;LEU A 406;THR A 421;TRP A 423;CYH A 424;LEU A 459;GLY A 485","SM5 A   1 (-4.3A);SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);SM5 A   1 (-4.3A);None;SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 ( 4.4A);None;None","0.93A","1uwjB-3omvA:13.4","1uwjA-3omvA:72.70"],["1UWJ_B_BAXB1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",10,"ILE A 355;VAL A 363;ALA A 373;LEU A 406;THR A 421;TRP A 423;CYH A 424;LEU A 459;HIS A 466;GLY A 485","SM5 A   1 (-4.3A);SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);None;SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 ( 4.4A);None;None;None","0.72A","1uwjB-3omvA:13.4","1uwjB-3omvA:72.70"],["1VPT_A_SAMA400_0","VP39","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",5,"LEU A 397;GLY A 488;VAL A 374;ALA A 373;LEU A 351","None;None;None;SM5 A   1 (-3.6A);None","0.93A","1vptA-3omvA:undetectable","1uwjB-3omvA:72.70"],["3GCS_A_BAXA401_1","MITOGEN-ACTIVATED PROTEIN KINASE 14","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",5,"ALA A 373;GLU A 393;LEU A 397;THR A 421;HIS A 466","SM5 A   1 (-3.6A);SM5 A   1 (-4.3A);None;SM5 A   1 (-4.4A);None","0.89A","3gcsA-3omvA:19.9","1vptA-3omvA:22.07"],["3GCS_A_BAXA401_1","MITOGEN-ACTIVATED PROTEIN KINASE 14","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",5,"VAL A 363;ALA A 373;GLU A 393;LEU A 397;THR A 421","SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);SM5 A   1 (-4.3A);None;SM5 A   1 (-4.4A)","0.59A","3gcsA-3omvA:19.9","3gcsA-3omvA:27.13"],["3HEC_A_STIA1_1","MITOGEN-ACTIVATED PROTEIN KINASE 14","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",5,"ALA A 373;LYS A 375;GLU A 393;LEU A 397;THR A 421","SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);SM5 A   1 (-4.3A);None;SM5 A   1 (-4.4A)","0.65A","3hecA-3omvA:20.6","3gcsA-3omvA:27.13"],["3HEG_A_BAXA1_1","MITOGEN-ACTIVATED PROTEIN KINASE 14","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"VAL A 363;ALA A 373;LYS A 375;GLU A 393;LEU A 397;THR A 421","SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);SM5 A   1 (-4.3A);None;SM5 A   1 (-4.4A)","0.59A","3hegA-3omvA:20.2","3hecA-3omvA:27.66"],["3MSS_D_STID1_2","TYROSINE-PROTEIN KINASE ABL1","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",4,"VAL A 363;LYS A 375;VAL A 396;ILE A 419","SM5 A   1 (-4.0A);SM5 A   1 (-3.5A);None;SM5 A   1 ( 4.3A)","0.73A","3mssD-3omvA:26.6","3hegA-3omvA:27.66"],["3OG7_A_032A1_1","AKAP9-BRAF FUSION PROTEIN","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",10,"ILE A 355;VAL A 363;ALA A 373;LEU A 397;LEU A 406;THR A 421;TRP A 423;CYH A 424;PHE A 475;PHE A 487","SM5 A   1 (-4.3A);SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);None;None;SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 ( 4.4A);SM5 A   1 (-3.0A);None","0.79A","3og7A-3omvA:34.5","3mssD-3omvA:29.03"],["3OG7_A_032A1_1","AKAP9-BRAF FUSION PROTEIN","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",10,"ILE A 355;VAL A 363;ALA A 373;LYS A 375;LEU A 397;LEU A 406;THR A 421;TRP A 423;PHE A 475;PHE A 487","SM5 A   1 (-4.3A);SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);None;None;SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 (-3.0A);None","0.81A","3og7A-3omvA:34.5","3og7A-3omvA:72.09"],["3OG7_A_032A1_1","AKAP9-BRAF FUSION PROTEIN","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"ILE A 355;VAL A 363;ALA A 373;LYS A 375;TRP A 423;PHE A 475;GLY A 488","SM5 A   1 (-4.3A);SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);SM5 A   1 (-4.3A);SM5 A   1 (-3.0A);None","1.05A","3og7A-3omvA:34.5","3og7A-3omvA:72.09"],["3OG7_A_032A1_1","AKAP9-BRAF FUSION PROTEIN","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"ILE A 355;VAL A 363;ALA A 373;TRP A 423;CYH A 424;PHE A 475;GLY A 488","SM5 A   1 (-4.3A);SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);SM5 A   1 (-4.3A);SM5 A   1 ( 4.4A);SM5 A   1 (-3.0A);None","0.97A","3og7A-3omvA:34.5","3og7A-3omvA:72.09"],["3OHT_A_1N1A1000_1","P38A","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"GLY A 356;VAL A 363;ALA A 373;LYS A 375;LEU A 397;THR A 421","SM5 A   1 ( 4.9A);SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);None;SM5 A   1 (-4.4A)","0.72A","3ohtA-3omvA:16.9","3og7A-3omvA:72.09"],["4RZV_A_032A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"ALA A 373;LEU A 406;ILE A 419;THR A 421;SER A 427;SER A 428;PHE A 475","SM5 A   1 (-3.6A);None;SM5 A   1 ( 4.3A);SM5 A   1 (-4.4A);None;None;SM5 A   1 (-3.0A)","0.77A","4rzvA-3omvA:12.9","3ohtA-3omvA:29.09"],["4RZV_A_032A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",9,"ALA A 373;LEU A 406;ILE A 419;THR A 421;TRP A 423;SER A 427;PHE A 475;GLY A 485;PHE A 487","SM5 A   1 (-3.6A);None;SM5 A   1 ( 4.3A);SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);None;SM5 A   1 (-3.0A);None;None","0.85A","4rzvA-3omvA:12.9","4rzvA-3omvA:70.53"],["4RZV_A_032A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",5,"ALA A 373;LEU A 406;THR A 421;TRP A 423;SER A 427","SM5 A   1 (-3.6A);None;SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);None","0.98A","4rzvA-3omvA:12.9","4rzvA-3omvA:70.53"],["4RZV_A_032A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"ALA A 373;LYS A 375;ILE A 419;THR A 421;SER A 427;SER A 428;PHE A 475","SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);SM5 A   1 ( 4.3A);SM5 A   1 (-4.4A);None;None;SM5 A   1 (-3.0A)","0.80A","4rzvA-3omvA:12.9","4rzvA-3omvA:70.53"],["4RZV_A_032A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",9,"ALA A 373;LYS A 375;ILE A 419;THR A 421;TRP A 423;SER A 427;PHE A 475;GLY A 485;PHE A 487","SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);SM5 A   1 ( 4.3A);SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);None;SM5 A   1 (-3.0A);None;None","0.87A","4rzvA-3omvA:12.9","4rzvA-3omvA:70.53"],["4RZV_A_032A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",8,"ALA A 373;LYS A 375;ILE A 419;TRP A 423;SER A 427;PHE A 475;GLY A 485;GLY A 488","SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);SM5 A   1 ( 4.3A);SM5 A   1 (-4.3A);None;SM5 A   1 (-3.0A);None;None","1.21A","4rzvA-3omvA:12.9","4rzvA-3omvA:70.53"],["4RZV_A_032A801_2","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",4,"ILE A 355;VAL A 363;PHE A 408;CYH A 424","SM5 A   1 (-4.3A);SM5 A   1 (-4.0A);None;SM5 A   1 ( 4.4A)","0.46A","4rzvA-3omvA:12.9","4rzvA-3omvA:70.53"],["4RZV_B_032B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"VAL A 363;ALA A 373;LEU A 406;THR A 421;TRP A 423;CYH A 424;SER A 427","SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);None;SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 ( 4.4A);None","1.05A","4rzvB-3omvA:33.1","4rzvA-3omvA:70.53"],["4RZV_B_032B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",10,"VAL A 363;ALA A 373;LYS A 375;LEU A 406;THR A 421;TRP A 423;CYH A 424;PHE A 475;GLY A 485;PHE A 487","SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);None;SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 ( 4.4A);SM5 A   1 (-3.0A);None;None","0.95A","4rzvB-3omvA:33.1","4rzvB-3omvA:70.53"],["4RZV_B_032B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",9,"VAL A 363;ALA A 373;LYS A 375;LEU A 406;THR A 421;TRP A 423;CYH A 424;SER A 428;PHE A 475","SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);None;SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 ( 4.4A);None;SM5 A   1 (-3.0A)","1.00A","4rzvB-3omvA:33.1","4rzvB-3omvA:70.53"],["4RZV_B_032B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",8,"VAL A 363;ALA A 373;LYS A 375;TRP A 423;CYH A 424;PHE A 475;GLY A 485;GLY A 488","SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);SM5 A   1 (-4.3A);SM5 A   1 ( 4.4A);SM5 A   1 (-3.0A);None;None","1.30A","4rzvB-3omvA:33.1","4rzvB-3omvA:70.53"],["4XV2_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"ALA A 373;LYS A 375;THR A 421;PHE A 475;GLY A 485;PHE A 487","SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);SM5 A   1 (-4.4A);SM5 A   1 (-3.0A);None;None","0.83A","4xv2A-3omvA:35.1","4rzvB-3omvA:70.53"],["4XV2_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",9,"VAL A 363;ALA A 373;LEU A 406;THR A 421;TRP A 423;CYH A 424;PHE A 475;GLY A 485;PHE A 487","SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);None;SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 ( 4.4A);SM5 A   1 (-3.0A);None;None","0.78A","4xv2A-3omvA:35.1","4xv2A-3omvA:72.04"],["4XV2_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",9,"VAL A 363;ALA A 373;LEU A 406;TRP A 423;CYH A 424;PHE A 475;GLY A 485;ASP A 486;PHE A 487","SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);None;SM5 A   1 (-4.3A);SM5 A   1 ( 4.4A);SM5 A   1 (-3.0A);None;SM5 A   1 (-3.5A);None","1.09A","4xv2A-3omvA:35.1","4xv2A-3omvA:72.04"],["4XV2_A_P06A801_2","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",4,"GLY A 358;LEU A 397;PHE A 408;ILE A 419","None;None;None;SM5 A   1 ( 4.3A)","0.71A","4xv2A-3omvA:35.1","4xv2A-3omvA:72.04"],["4XV2_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",9,"ALA A 373;LEU A 397;LEU A 406;THR A 421;TRP A 423;CYH A 424;PHE A 475;GLY A 485;PHE A 487","SM5 A   1 (-3.6A);None;None;SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 ( 4.4A);SM5 A   1 (-3.0A);None;None","0.77A","4xv2B-3omvA:35.4","4xv2A-3omvA:72.04"],["4XV2_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",8,"ALA A 373;LEU A 406;TRP A 423;CYH A 424;PHE A 475;GLY A 485;ASP A 486;PHE A 487","SM5 A   1 (-3.6A);None;SM5 A   1 (-4.3A);SM5 A   1 ( 4.4A);SM5 A   1 (-3.0A);None;SM5 A   1 (-3.5A);None","0.99A","4xv2B-3omvA:35.4","4xv2B-3omvA:72.04"],["4XV2_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"ALA A 373;LYS A 375;LEU A 397;THR A 421;PHE A 475;GLY A 485;PHE A 487","SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);None;SM5 A   1 (-4.4A);SM5 A   1 (-3.0A);None;None","0.89A","4xv2B-3omvA:35.4","4xv2B-3omvA:72.04"],["4XV2_B_P06B801_2","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",4,"GLY A 358;VAL A 363;PHE A 408;ILE A 419","None;SM5 A   1 (-4.0A);None;SM5 A   1 ( 4.3A)","0.44A","4xv2B-3omvA:35.4","4xv2B-3omvA:72.04"],["5CSW_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",10,"VAL A 363;ALA A 373;LEU A 397;LEU A 406;THR A 421;TRP A 423;CYH A 424;PHE A 475;GLY A 485;PHE A 487","SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);None;None;SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 ( 4.4A);SM5 A   1 (-3.0A);None;None","0.84A","5cswA-3omvA:35.4","4xv2B-3omvA:72.04"],["5CSW_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",9,"VAL A 363;ALA A 373;LYS A 375;LEU A 397;THR A 421;TRP A 423;PHE A 475;GLY A 485;PHE A 487","SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);None;SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 (-3.0A);None;None","0.95A","5cswA-3omvA:35.4","5cswA-3omvA:75.89"],["5CSW_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",8,"ALA A 373;LYS A 375;LEU A 397;THR A 421;TRP A 423;PHE A 475;GLY A 485;PHE A 487","SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);None;SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 (-3.0A);None;None","0.95A","5cswB-3omvA:34.5","5cswA-3omvA:75.89"],["5CSW_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",10,"VAL A 363;ALA A 373;LEU A 397;LEU A 406;THR A 421;TRP A 423;CYH A 424;PHE A 475;GLY A 485;PHE A 487","SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);None;None;SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 ( 4.4A);SM5 A   1 (-3.0A);None;None","0.85A","5cswB-3omvA:34.5","5cswB-3omvA:75.89"],["5H2U_B_1N1B501_1","PROTEIN-TYROSINE KINASE 6","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"VAL A 363;ALA A 373;LEU A 406;ILE A 419;THR A 421;GLY A 485;ASP A 486","SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);None;SM5 A   1 ( 4.3A);SM5 A   1 (-4.4A);None;SM5 A   1 (-3.5A)","0.80A","5h2uB-3omvA:19.6","5cswB-3omvA:75.89"],["5H2U_C_1N1C501_1","PROTEIN-TYROSINE KINASE 6","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",5,"ALA A 373;LEU A 406;ILE A 419;THR A 421;GLY A 485","SM5 A   1 (-3.6A);None;SM5 A   1 ( 4.3A);SM5 A   1 (-4.4A);None","0.64A","5h2uC-3omvA:27.1","5h2uB-3omvA:32.26"],["5H2U_D_1N1D504_1","PROTEIN-TYROSINE KINASE 6","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"VAL A 363;ALA A 373;LEU A 406;ILE A 419;THR A 421;GLY A 485","SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);None;SM5 A   1 ( 4.3A);SM5 A   1 (-4.4A);None","0.66A","5h2uD-3omvA:27.2","5h2uC-3omvA:32.26"],["5HES_B_032B401_1","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"VAL A 363;ALA A 373;LYS A 375;ILE A 419;THR A 421;PHE A 487","SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);SM5 A   1 ( 4.3A);SM5 A   1 (-4.4A);None","0.78A","5hesB-3omvA:26.1","5h2uD-3omvA:32.26"],["5HI2_A_BAXA801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",10,"ALA A 373;LYS A 375;GLU A 393;LEU A 397;LEU A 406;THR A 421;TRP A 423;CYH A 424;LEU A 459;GLY A 485","SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);SM5 A   1 (-4.3A);None;None;SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 ( 4.4A);None;None","0.95A","5hi2A-3omvA:33.4","5hesB-3omvA:30.58"],["5HI2_A_BAXA801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",10,"ALA A 373;LYS A 375;LEU A 397;LEU A 406;THR A 421;TRP A 423;CYH A 424;LEU A 459;HIS A 466;GLY A 485","SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);None;None;SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 ( 4.4A);None;None;None","0.82A","5hi2A-3omvA:33.4","5hi2A-3omvA:71.71"],["5HIE_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",8,"GLY A 358;ALA A 373;LYS A 375;LEU A 406;ILE A 419;THR A 421;PHE A 475;GLY A 485","None;SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);None;SM5 A   1 ( 4.3A);SM5 A   1 (-4.4A);SM5 A   1 (-3.0A);None","0.92A","5hieA-3omvA:34.7","5hi2A-3omvA:71.71"],["5HIE_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"GLY A 358;VAL A 363;ALA A 373;LEU A 397;ILE A 419;THR A 421;TRP A 423","None;SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);None;SM5 A   1 ( 4.3A);SM5 A   1 (-4.4A);SM5 A   1 (-4.3A)","1.02A","5hieA-3omvA:34.7","5hieA-3omvA:77.85"],["5HIE_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",9,"GLY A 358;VAL A 363;ALA A 373;LEU A 406;ILE A 419;THR A 421;TRP A 423;PHE A 475;GLY A 485","None;SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);None;SM5 A   1 ( 4.3A);SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 (-3.0A);None","0.79A","5hieA-3omvA:34.7","5hieA-3omvA:77.85"],["5HIE_A_P06A801_2","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",4,"ILE A 355;CYH A 424;ASP A 486;PHE A 487","SM5 A   1 (-4.3A);SM5 A   1 ( 4.4A);SM5 A   1 (-3.5A);None","0.91A","5hieA-3omvA:34.7","5hieA-3omvA:77.85"],["5HIE_A_P06A801_2","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",4,"ILE A 355;GLY A 356;PHE A 408;CYH A 424","SM5 A   1 (-4.3A);SM5 A   1 ( 4.9A);None;SM5 A   1 ( 4.4A)","0.51A","5hieA-3omvA:34.7","5hieA-3omvA:77.85"],["5HIE_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"GLY A 358;ALA A 373;LYS A 375;LEU A 406;THR A 421;PHE A 475;GLY A 485","None;SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);None;SM5 A   1 (-4.4A);SM5 A   1 (-3.0A);None","0.91A","5hieB-3omvA:34.8","5hieA-3omvA:77.85"],["5HIE_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",9,"GLY A 358;VAL A 363;ALA A 373;LEU A 406;ILE A 419;THR A 421;TRP A 423;PHE A 475;GLY A 485","None;SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);None;SM5 A   1 ( 4.3A);SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 (-3.0A);None","0.81A","5hieB-3omvA:34.8","5hieB-3omvA:77.85"],["5HIE_B_P06B801_2","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",5,"ILE A 355;GLY A 356;CYH A 424;ASP A 486;PHE A 487","SM5 A   1 (-4.3A);SM5 A   1 ( 4.9A);SM5 A   1 ( 4.4A);SM5 A   1 (-3.5A);None","1.10A","5hieB-3omvA:34.8","5hieB-3omvA:77.85"],["5HIE_B_P06B801_2","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",4,"ILE A 355;GLY A 356;LEU A 397;PHE A 408","SM5 A   1 (-4.3A);SM5 A   1 ( 4.9A);None;None","0.87A","5hieB-3omvA:34.8","5hieB-3omvA:77.85"],["5HIE_B_P06B801_2","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",4,"ILE A 355;GLY A 356;PHE A 408;CYH A 424","SM5 A   1 (-4.3A);SM5 A   1 ( 4.9A);None;SM5 A   1 ( 4.4A)","0.50A","5hieB-3omvA:34.8","5hieB-3omvA:77.85"],["5HIE_C_P06C801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",9,"GLY A 356;GLY A 358;VAL A 363;ALA A 373;LEU A 406;THR A 421;TRP A 423;PHE A 475;GLY A 485","SM5 A   1 ( 4.9A);None;SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);None;SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 (-3.0A);None","0.78A","5hieC-3omvA:34.8","5hieB-3omvA:77.85"],["5HIE_C_P06C801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"GLY A 358;ALA A 373;LYS A 375;LEU A 406;THR A 421;PHE A 475;GLY A 485","None;SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);None;SM5 A   1 (-4.4A);SM5 A   1 (-3.0A);None","0.89A","5hieC-3omvA:34.8","5hieC-3omvA:77.85"],["5HIE_C_P06C801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"VAL A 363;ALA A 373;LEU A 406;TRP A 423;PHE A 475;GLY A 485;ASP A 486","SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);None;SM5 A   1 (-4.3A);SM5 A   1 (-3.0A);None;SM5 A   1 (-3.5A)","1.17A","5hieC-3omvA:34.8","5hieC-3omvA:77.85"],["5HIE_C_P06C801_2","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",4,"ILE A 355;ILE A 419;CYH A 424;PHE A 487","SM5 A   1 (-4.3A);SM5 A   1 ( 4.3A);SM5 A   1 ( 4.4A);None","0.69A","5hieC-3omvA:34.8","5hieC-3omvA:77.85"],["5HIE_C_P06C801_2","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",4,"ILE A 355;PHE A 408;ILE A 419;ASN A 472","SM5 A   1 (-4.3A);None;SM5 A   1 ( 4.3A);SM5 A   1 (-3.9A)","0.70A","5hieC-3omvA:34.8","5hieC-3omvA:77.85"],["5HIE_C_P06C801_2","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",4,"ILE A 355;PHE A 408;ILE A 419;CYH A 424","SM5 A   1 (-4.3A);None;SM5 A   1 ( 4.3A);SM5 A   1 ( 4.4A)","0.46A","5hieC-3omvA:34.8","5hieC-3omvA:77.85"],["5HIE_C_P06C801_2","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",4,"VAL A 396;PHE A 408;ILE A 419;ASN A 472","None;None;SM5 A   1 ( 4.3A);SM5 A   1 (-3.9A)","0.98A","5hieC-3omvA:34.8","5hieC-3omvA:77.85"],["5HIE_D_P06D801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",8,"GLY A 358;ALA A 373;LYS A 375;LEU A 406;ILE A 419;THR A 421;PHE A 475;GLY A 485","None;SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);None;SM5 A   1 ( 4.3A);SM5 A   1 (-4.4A);SM5 A   1 (-3.0A);None","0.93A","5hieD-3omvA:34.6","5hieC-3omvA:77.85"],["5HIE_D_P06D801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",9,"GLY A 358;VAL A 363;ALA A 373;LEU A 406;ILE A 419;THR A 421;TRP A 423;PHE A 475;GLY A 485","None;SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);None;SM5 A   1 ( 4.3A);SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 (-3.0A);None","0.79A","5hieD-3omvA:34.6","5hieD-3omvA:77.85"],["5HIE_D_P06D801_2","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",5,"ILE A 355;GLY A 356;CYH A 424;ASP A 486;PHE A 487","SM5 A   1 (-4.3A);SM5 A   1 ( 4.9A);SM5 A   1 ( 4.4A);SM5 A   1 (-3.5A);None","1.08A","5hieD-3omvA:34.6","5hieD-3omvA:77.85"],["5HIE_D_P06D801_2","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",4,"ILE A 355;GLY A 356;PHE A 408;ASN A 472","SM5 A   1 (-4.3A);SM5 A   1 ( 4.9A);None;SM5 A   1 (-3.9A)","0.88A","5hieD-3omvA:34.6","5hieD-3omvA:77.85"],["5HIE_D_P06D801_2","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",4,"ILE A 355;GLY A 356;PHE A 408;CYH A 424","SM5 A   1 (-4.3A);SM5 A   1 ( 4.9A);None;SM5 A   1 ( 4.4A)","0.50A","5hieD-3omvA:34.6","5hieD-3omvA:77.85"],["5VCV_A_1N1A404_1","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"ALA A 373;LYS A 375;GLU A 393;THR A 421;PHE A 475;GLY A 485","SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);SM5 A   1 (-4.3A);SM5 A   1 (-4.4A);SM5 A   1 (-3.0A);None","0.83A","5vcvA-3omvA:23.1","5hieD-3omvA:77.85"],["5VCY_A_DB8A401_1","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","3omv","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"VAL A 363;ALA A 373;LYS A 375;GLU A 393;THR A 421;CYH A 424;PHE A 475","SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);SM5 A   1 (-4.3A);SM5 A   1 (-4.4A);SM5 A   1 ( 4.4A);SM5 A   1 (-3.0A)","0.98A","5vcyA-3omvA:23.1","5vcvA-3omvA:27.99"]]